IN THE CLAIMS

Please replace all prior versions and claims listings with the following claims listing <u>Claims Listing</u>:

- 1-2. (cancel)
- 3. (currently amended) A method for detecting aberrant promoter methylation associated with predisposition for cancers of the breast, lung, and colon, in a human comprising detecting methylation of the PAX5 β gene A method of monitoring for cancer in a biological specimen containing DNA from cells suspected of being cancerous and having PAX5 β genespecific promoter methylation comprising the steps of:

subjecting DNA to bisulfite modification;

expanding the number of copies of at least a portion of the PAX5 β gene by a polymerase chain reaction to amplify the portion of the PAX5 β gene where the promoter methylation resides, thereby generating an amplification product; and

using an aliquot of the amplification product generated by the first polymerase chain reaction in a second, methylation-specific, polymerase chain reaction at a temperature of annealing that exceeds the melting temperature of the second primer set to amplify a portion of the gene's CpG island where the promoter methylation resides and detect the presence of inactivation of the PAX5 β gene.

.

4-6. (cancel)

7. (currently amended) A method of monitoring for cancer in a biological specimen containing DNA from cells suspected of being cancerous and having PAX5 α genespecific promoter methylation human, comprising detecting gene inactivation in a biological fluid by ascertaining the presence of gene-specific promoter methylation in the cells of the biological fluid, and further comprising the steps of:

subjecting DNA in the biological fluid to bisulfite modification;

expanding the number of copies of <u>at least a portion of the PAX5</u> α gene <u>by using</u> in the DNA by using primer sequences which recognize the bisulfite-modified DNA template, but which not discriminate between methylated and unmethylated alleles, in a polymerase chain reaction to amplify a CpG-rich portion of the PAX5 α gene where the promoter methylation resides, thereby generating an amplification product containing fragments of the PAX5 α gene; and

using an aliquot of the amplification product generated by the first polymerase chain reaction in a second, methylation-specific, polymerase chain reaction employing primer sequences specific to a methylated DNA template to at a temperature of annealing that exceeds the melting temperature of the second primer set to amplify a portion of the gene's CpG island where the promoter methylation resides and detect the presence of inactivation of the PAX5 α gene

Serial Number: 10/815,198

Filing Date: March 25, 2004

Title: Cancer Monitoring by Aberrant Promotor Methylation of the Transcription Factor Genes PAX5 Alpha PAX5 Beta, Novel Loop Helix Loop

Protein, Novel Gene 2, and Beta 3 Genes

10. (new) The method of claim 3 wherein the step of expanding at least a portion of the PAX5 β gene comprises amplifying a 328 base pair fragment with a primer set comprising:

Forward 5' agtttgtgggttgtttagttaatgg

Reverse 5' caaaaaatcccaaccaccaaaacc

- 11. (new) The method of claim 3 wherein the biological sample from which the DNA is obtained is selected from tissue, plasma, ejaculate, cerebrospinal fluid, serum, mammary duct fluid, urine, fecal stool, and sputum.
- 12. (new) The method of claim 7 wherein the step of expanding at least a portion of the PAX5 α gene comprises amplifying a 389 base pair fragment with a primer set comprising:

Forward 5' gggtttgtatatggagatgttatagg

Reverse 5' caacatcacaaaatatccccaaacac

13. (new) The method of claim 7 wherein the biological sample from which the DNA is obtained is selected from tissue, plasma, ejaculate, cerebrospinal fluid, serum, mammary duct fluid, urine, fecal stool, and sputum.